Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy (IgAN) Round brings in new biotech investors, Gilde Healthcare, Sofinnova...

ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma (STS) subtypes The Phase I/II ADCElerate-01 trial is designed to evaluate...

Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, announces the acquisition of Alderley Analytical Ltd, based in Manchester, UK. The transaction marks an important milestone in Synexa’s ‘buy and build’ growth strategy, underpinning...